Mirador Therapeutics
Unknown, Bahamas · Biotechnology · 35 employees
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
Funding history
- Series B — $250.0M — Jan 2026
- Venture - Series Unknown — $333.0M — Apr 2024
- Venture - Series Unknown — $80.0M — Apr 2024
- Series A — $400.0M — Mar 2024
Recent signals
- Jan 11, 2026: Raised $250.0M in Series B
- Sep 17, 2024: Mirador Therapeutics Appoints Gregg Gilbert as Chief Financial Officer
- Apr 03, 2024: Raised $333.0M in Venture - Series Unknown
- Apr 03, 2024: Raised $80.0M in Venture - Series Unknown
- Mar 21, 2024: Raised $400.0M in Series A
See plans & pricing → Track Mirador Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.